- Home
- ACAD vs PAGP Comparison
ACAD vs PAGP Comparison
Compare ACAD & PAGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- PAGP
- Stock Information
- Founded
- ACAD 1993
- PAGP 2013
- Country
- ACAD United States
- PAGP United States
- Employees
- ACAD N/A
- PAGP N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- PAGP Natural Gas Distribution
- Sector
- ACAD Health Care
- PAGP Energy
- Exchange
- ACAD Nasdaq
- PAGP Nasdaq
- Market Cap
- ACAD 4.3B
- PAGP 3.6B
- IPO Year
- ACAD 2004
- PAGP 2013
- Fundamental
- Price
- ACAD $23.61
- PAGP $18.70
- Analyst Decision
- ACAD Buy
- PAGP Hold
- Analyst Count
- ACAD 21
- PAGP 8
- Target Price
- ACAD $29.30
- PAGP $20.29
- AVG Volume (30 Days)
- ACAD 1.9M
- PAGP 1.3M
- Earning Date
- ACAD 11-05-2025
- PAGP 11-07-2025
- Dividend Yield
- ACAD N/A
- PAGP 8.15%
- EPS Growth
- ACAD 615.00
- PAGP N/A
- EPS
- ACAD 1.33
- PAGP 0.69
- Revenue
- ACAD $1,018,885,000.00
- PAGP $47,796,000,000.00
- Revenue This Year
- ACAD $14.01
- PAGP N/A
- Revenue Next Year
- ACAD $11.72
- PAGP $17.44
- P/E Ratio
- ACAD $17.82
- PAGP $27.09
- Revenue Growth
- ACAD 14.41
- PAGP N/A
- 52 Week Low
- ACAD $13.40
- PAGP $16.61
- 52 Week High
- ACAD $26.65
- PAGP $22.31
- Technical
- Relative Strength Index (RSI)
- ACAD 39.78
- PAGP 44.35
- Support Level
- ACAD $23.70
- PAGP $18.40
- Resistance Level
- ACAD $25.90
- PAGP $18.74
- Average True Range (ATR)
- ACAD 0.74
- PAGP 0.29
- MACD
- ACAD -0.33
- PAGP -0.01
- Stochastic Oscillator
- ACAD 8.16
- PAGP 44.14
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About PAGP Plains GP Holdings L.P. Units representing Limited Partner Interests
Plains GP Holdings LP provides transportation, storage, processing, fractionation, and marketing services for crude oil, refined products, natural gas liquids, liquefied petroleum gas, and related products. The group manages its operations through two operating segments: Crude Oil and NGL.